NCT04850014

Brief Summary

Childhood obesity is increasing globally. Changes in body composition and physiology in obesity setting modify pharmacokinetic parameters and might increase the risk in case of poisoning. Acetaminophen is a drug often implied in poisoning in children population, especially in adolescent attempting suicide. In practice, clinicians use weight to assess intoxication severity, but depending on the weight chosen (actual weight, lean body weight, ideal weight,..) the severity assessment can change as well as medical care needed. In this context we hypothesize that a PBPK modelling would be helpful to predict toxic dosing in obese population and especially in obese adolescent or children. The primary objective of this study is to collect data related to acetaminophen-poisoned patient with at least one acetaminophen concentration sampling and whose clinical outcome is known in order to refine and validate such a PBPK model.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2021

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

April 14, 2021

Completed
6 days until next milestone

First Posted

Study publicly available on registry

April 20, 2021

Completed
11 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2021

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2021

Completed
Last Updated

April 20, 2021

Status Verified

April 1, 2021

Enrollment Period

4 months

First QC Date

April 14, 2021

Last Update Submit

April 14, 2021

Conditions

Keywords

PBPKModellingAcetaminophenParacetamolPediatricsObesityPharmacokineticsToxicokineticsPoisoning

Outcome Measures

Primary Outcomes (1)

  • Acetaminophen concentration

    With hour post-ingestion provided

    31 october 2021

Study Arms (2)

Poisoned patients

All subjects with paracetamolemia in the context of paracetamol poisoning

Other: AnthropomorphismOther: Relevant clinical datas

Control group

Acetaminophen-poisoned patient being non-obese

Other: AnthropomorphismOther: Relevant clinical datas

Interventions

Height, weight, body surface area, body mass index, exact age (date of birth or age in days, months and years), falling which year of birth gender

Control groupPoisoned patients

Medical history Concomitant medication Paracetamol intake : dosage, delay, context, route of intake Alcohol intake Smoking status (including active and passive exposition or no exposition) Curative treatment / Antidote / purifying treatment received and time of introduction Clinical signs, Acetaminophen concentration in plasma with associated accurate time of sampling (date, hour and time following acetaminophen intake Liver and kindney function assessment by measure measuring plasma concentration of: AST, ALT, Factor V, Prothrombin, APTT, INR, albuminemia, bilirubin, phosphorus, pH, creatitine. And GFR estimation. Imaging.

Control groupPoisoned patients

Eligibility Criteria

Age10 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

* Poisoned acetaminophen subjects * At least one acetaminophen blood sample result available in data base

You may qualify if:

  • All subjects \>/= 10 year old
  • Availability of at least one positive acetaminophen concentration with its associated sampling time
  • Known clinical outcome

You may not qualify if:

  • \< 10 year old
  • lack of data-

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospices Civils de Lyon

Lyon, 69000, France

RECRUITING

MeSH Terms

Conditions

PoisoningObesity

Condition Hierarchy (Ancestors)

Chemically-Induced DisordersOverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 14, 2021

First Posted

April 20, 2021

Study Start

January 1, 2021

Primary Completion

May 1, 2021

Study Completion

October 1, 2021

Last Updated

April 20, 2021

Record last verified: 2021-04

Locations